Research programme: biosimilars - ARA Healthcare

Drug Profile

Research programme: biosimilars - ARA Healthcare

Alternative Names: ARABS 1; ARABS 2; ARABS 3; ARABS 4; ARABS 5; ARABS 6; ARABS 7; ARABS 8

Latest Information Update: 11 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARA Healthcare
  • Class Enzymes; Interferons; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma; Rheumatoid arthritis
  • Research Cancer; Crohn's disease; Hairy cell leukaemia; Hepatitis C; Inflammation; Multiple sclerosis

Most Recent Events

  • 18 May 2015 Early research in Cancer in India (Parenteral) before May 2015 (ARA Healthcare pipeline, May 2015)
  • 18 May 2015 Early research in Crohn's disease in India (Parenteral) before May 2015 (ARA Healthcare pipeline, May 2015)
  • 18 May 2015 Early research in Hairy cell leukaemia in India (Parenteral) before May 2015 (ARA Healthcare pipeline, May 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top